n n n ‘.concat(e.i18n.t(“search.voice.recognition_retry”),’n
GOTHENBURG, SWEDEN / ACCESSWIRE / December 22, 2023 / XVIVO Ab Infusion (STO:XVIVO)(LSE:0RKL)(FRA:3XV) In 2014, XVIVO brought to the Italian market a state-of-the-art generation of liver, designed for oxygenated perfusion prior to transplantation. Today, we are proud to announce that we have reached the milestone of 1,200 infusions of XVIVO’s Liver Assist device in Italy. Mechanical perfusion leads to better outcomes and the use of more donated organs to save many lives. Currently, 16 of the 22 liver transplant centers in Italy use the 16th generation, adding leading high-volume hospitals.
In recent years, Italy has seen approximately 1,400 liver transplants performed annually. About a quarter of these transplant procedures are performed with machine perfusion. In 2023 nearly 400 liver transplants will be performed using XVIVO’s Liver Assist. The technology improves patient outcomes after transplantation and allows for assessment of donor livers that historically would not have been accepted for transplantation, thereby increasing the utilization of donated organs. XVIVO’s Liver Assist is being used for various types of donor livers, including those from donors who have deceased due to circulatory death (DCD), those from elderly and overweight donors, but the technology also provides the opportunity of safely splitting a liver for transplantation into two patients.
The service concept presented through XVIVO in Italy includes the control of the infusion procedure and the technical expertise of a perfusionist. This has proven to be very effective and the business style has shown steady expansion year after year.
In Italy, three renowned transplant surgeons have played a pivotal role in the implementation and progression of machine-based liver perfusion.
“In 2015, at Niguarda Hospital we were the first hospital to begin transplanting organs from deceased circulating donors with this generation to evaluate the capacity of the organs after 20 minutes of flat electrocardiogram, which is mandatory in our country,” explains the professor. Luciano De Carlis, Director of General and Transplant Surgery at Niguarda Hospital and President of the Italian Society of Organ Transplants (SITO), Milan, Italy. “Over time, we’ve been able to show that through this generation, we’ve taken a step forward in organ quality and the transplant process. “
Dr. Davide Ghinolfi, acting director of the Liver Surgery and Transplantation Unit at the University Hospital of Pisa, Italy, adds: “Perfusion devices allow the use of livers according to broad criteria, such as elderly donors, fatty livers and other conditions that in the afterlife led to organ rejection. Today, we can remove many organs with this technology. For example, in Pisa, the liver of a donor over a hundred years old was effectively transplanted into a patient who was still alive. Smart Fitness after more than a year.
These are some of the facets that have allowed Italy to become the world’s largest user of the Liver Assist generation. Reflecting on the future, Professor Renato Romagnoli, Director of General Surgery S. C. 2U at the Liver Transplant Center, P. O. Molinette, Turin, Italy, says: “This generation has unexplored limits because the reports obtained so far in studies have shown that it is It is imaginable to maintain or even treat the liver not only for a few days, but even for weeks. They have the ability to use perfusion to regenerate, modify or fix those organs, in order to transplant more organs and optimize the results.
“Italy is now the largest market for XVIVO liver infusion. Since its appearance in 2014, we have noticed a steady increase in its use, year after year, with an acceleration in recent years. Today, around 25-30% of all transplanted livers in Italy have been infused with the XVIVO generation and I am sure that in the next two years this figure will reach 50%. Let no one die while waiting for a new organ,” says Christoffer Rosenblad, CEO of XVIVO.
December 22, 2023GothenburgChristoffer Rosenblad, CEOXVIVO Infusion AB (publ)
For information, please contact:
Christoffer Rosenblad, Chief Executive Officer, 46 519 21 59, Email: christoffer. rosenblad@xvivogroup. com Kristoffer Nordström, Chief Financial Officer, 46 519 21 64, Email: kristoffer. nordstrom@xvivogroup. com
About us
Founded in 1998, XVIVO is the medical generation corporation committed to extending the life of all primary organs so that transplant groups around the world can save more lives. Our answers allow renowned doctors and scholars to overcome the barriers of transplant medicine. XVIVO is headquartered in Gothenburg, Sweden, with offices and studio locations on two continents. The company is indexed on the Nasdaq and carries the symbol XVIVO. More information can be found on the website www. xvivogroup. com.
Attachments
XVIVO reaches a milestone in Italy: 1,200 life-saving infusions with Liver Assist
SOURCE: XVIVO Infusion AB
View the original press release on accesswire.com